m-PEG4-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

m-PEG8-Amine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

N-Boc-diethanolamine is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).

Gemifloxacin mesylate (trade name Factive, Oscient Pharmaceuticals) is an oral broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia.

A novel platelet inhibitor

1-Azakenpaullone is a potent and ATP-competitive GSK-3β (glycogen synthase kinase-3β) inhibitor (IC₅₀ = 18 nM).

SC-560 is a member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors which includes celecoxib (Celebrex™) and rofecoxib (Vioxx™).

LY3177833 is a novel CDC7 inhibitor,CDC7/DBF4 IC50 = 3.3 nM, pMCM2 (S53) IC50 = 290 nM and IVTI TEC70 = 1.6 mcM.

LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor.

LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.

LY900009 (LY-900009) is an orally active small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.

LYN-1604 is a potential ULK1 agonist with IC50 of 1.66 μM against MDA-MB-231 cells and it binds to wild-type ULK1 with a binding affinity in the nanomole range (Kd=291.4 nM).

MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.

mAChR-IN-1 is a potent muscarinic cholinergic receptor(mAChR) antagonist with IC50 of 17 nM..

Calmodulin antagonist. Inhibits Ca2+-calmodulin-dependent phosphodiesterase (IC50 = 28 μM) and myosin light chain kinase (IC50 = 51 μM).

TPCA-1 is potent, selective inhibitor of IKK-2 (IC50 = 17.9 nM) that displays>22-fold selectivity over IKK-1 and > 550-fold selectivity over other kinases and enzymes.

Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).

BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3.

MAK683 is a novel PRC2/EED inhibitor.

BQ-788 sodium salt is a potent, selective ETB receptor antagonist (IC50 = 1.2 nM for inhibition of ET-1 binding to human Girardi heart cells); poorly inhibited the binding to ET A receptors in human neuroblastoma cell line SK-N-MC cells (IC(50), 1300 nM).

Mavatrep is an orally bioavailable TRPV1 antagonist (Ki=6.5 nM), exhibits minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6.

Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).

BRACO19 is a telomerase inhibitor that stabilizes G-quadruplexes, targeting telomeric G-quadruplexes, inducing DNA damage and cell-cycle arrest.

MBP146-78 inhibits the growth of Eimeria spp. both in vitro and in vivo.

U-73122 is an inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase).

Epoxomicin is a selective and irreversible inhibitor of 20S proteasome with an IC50 value of 4 nM.

PF-5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε)

Exemestane(FCE 24304) is an aromatase inhibitor, inhibits human placental and rat ovarian aromatase with IC50 of 30 nM and 40 nM, respectively.

Almotriptan Malate is a 5-HT1B/1D-receptor agonist used to treat migraine.

ALLO-1 is a SMO antagonist that inhibits both wild-type (IC50 = 50 nM) and mutant SMO, including the D473H SMO mutant (IC50s = 300-1000 nM).